Elotuzumab Enhances CD16-Independent NK Cell-Mediated Cytotoxicity against Myeloma Cells by Upregulating Several NK Cell-Enhancing Genes

Figure 3

NK-92MI/CD16a (E, CD16-dependent) cell-mediated cytotoxicity against K562, U266, RPMI 8226, and MM.1S target (T) cells pretreated without or with Elo (10 μg/mL and/or 20 μg/mL), and their IFN-γ production: (a) LDH assay showing the cytotoxicity of NK-92MI/CD16a against various target cells, (b) FCM analyses of dead target cells (CFSE⁺FVD⁺) at E : T ratios of 1 : 1 and 2.5 : 1. MM.1S cells were also pretreated with Elo and incubated with NK-92MI/CD16a after washing, (c) degranulation of NK-92MI/CD16a was assessed as CD107a⁺CD56⁺ expression on various target cells, when target cells were pretreated without (−) or with Elo (E : T = 1 : 1), using FCM assay. gray bars, and (d) ELISA-based detection of IFN-γ production after coculture with NK-92MI/CD16a and target cells, pretreated without (dotted line) or with (solid line) 10 µg/mL of Elo. Results for (a)–(d) are presented as mean ± SD of three to five independent experiments. , , and .

(a)

(b)

(c)

(d)